Transdermal gabapentin penetration in cats

W19-039    Assessment of transdermal penetration of gabapentin in cats.
(A Winn-funded grant project final progress report)

Principal Investigators: Jennifer Slovak; Nicolas Villarino; New York City Animal Medical Center

The investigators have completed their study enrolling a total of 23 cats in the pilot transdermal gabapentin study. Initially, eight of the client-owned cats were administered transdermal gabapentin in a Lipoderm® base at a dose of either 5mg/kg TID for 5 days or 10mg/kg TID for 5 days.

After the initial data was analyzed, an additional 15 cats were enrolled and were administered transdermal gabapentin on the ear at 10mg/kg TID. Blood collection occurred prior to gabapentin administration, 24 hours and 5 days post initiating gabapentin.  All serum samples collected were trough samples, frozen at -80 and sent to the University of Tennessee’s Pharmacology Lab for analysis utilizing HPLC-mass spectroscopy.

The project is completed and the data prepared for a manuscript for publication.

Publications:
Abstract submission for the 2020 ACVIM Forum in June.  Manuscript in current preparation.

Presentations:
An oral abstract is planned for the 2020 ACVIM Forum in June.

Summary prepared for Winn Feline Foundation ©
 2020

See also:

Adrian D, Papich MG, et al. The pharmacokinetics of gabapentin in cats. J Vet Intern Med. 2018 Nov;32(6):1996-2002.